Study,Year,Data source,ID: CRS,ID: CTG,Char: Methods,Char: Participants,Char: Interventions,Char: Outcomes,Char: Identification,Char: Declarations of interest among primary researchers,Char: Notes
Carmi 2022,2022,PUB,23524746,NCT00855270,"<p><b>Study design: </b>RCT, parallel groups, double-blind, placebo-controlled</p><p><b>Number of centres: </b>1</p><p><b>Location: </b>Israel</p><p><b>Number of arms:</b> 2 (hydrocortisone versus placebo)</p><p><b>Follow-up time points:</b> 1, 3, 8 and 13 months after the traumatic event</p><p><b>Imputation strategy:</b> no imputation for missing values</p><p><b>Original study outcomes (name, measure, time points): </b>PTSD rate and symptoms severity (CAPS), anxiety (visual analogue scale for anxiety (VAS-A)) and depression (visual analogue scale for depression (VAS-D)), at 2 weeks, 1, 3, 8 and 13 months after the traumatic event</p>","<p><b>Sample size:</b> 118</p><p><b>Baseline characteristics</b></p><p>Hydrocortisone</p><ul><li><i>Participants with a history of previous trauma</i>: not reported</li><li><i>Type of traumatic event</i>: motor vehicle accident: 45, work accident: 4, violent attack: 2, rocket attacks: 0</li><li><i>Sex (F/M) and mean age (SD)</i>: 27/24, 38.1 (12.5)</li><li><i>Baseline acute traumatic stress symptoms (assessed before intervention administration):</i> VAS Distress: 3.22 (2.99), VAS anxiety: 3.39 (3.10)</li></ul><p>Placebo</p><ul><li><i>Participants with a history of previous trauma</i>: not reported</li><li><i>Type of traumatic event</i>: motor vehicle accident: 39, work accident: 3, violent attack: 2, rocket attacks: 1</li><li><i>Sex (F/M) and mean age (SD)</i>: 23/22, 40.4 (12.6)</li><li><i>Baseline acute traumatic stress symptoms (assessed before intervention administration): </i>VAS Distress: 3.45 (2.91), VAS anxiety: 3.62 (3.08)</li></ul><p><b>Baseline group differences: </b>no baseline group imbalances</p><p><b>Inclusion criteria: </b>admission to the emergency department of Chaim Sheba Medical Center, exposure to a traumatic event</p><p><b>Acute traumatic stress symptoms criteria:</b> modified DSM-IV acute stress response criteria: exposure to traumatic events, presenting at least 2 of the 5 dissociative symptoms, presence of anxiety or arousal, and significant distress</p><p><b>Exclusion criteria: </b>serious physical injury (a score of 3 or above on the Abbreviated Injury Scale), brain trauma, substance abuse disorders, cardiac pacemaker implant, a history of epilepsy, neurosurgery, hypersensitivity to hydrocortisone, pregnancy, treatment for asthma, medical (including psychiatric) conditions that may represent contraindications for hydrocortisone administration</p>","<p><b>Setting: </b>emergency department</p><p><b>Intervention characteristics</b></p><p>Hydrocortisone</p><ul><li><i>Number of randomised participants</i>: 60</li><li><i>Time from traumatic event to first intervention administration</i>: within 6 hours from the traumatic event</li><li><i>Intervention regimen</i>: single intravenous bolus at a dose based on body weight: 100 mg for weights of 60 to 69 kg, 120 mg for weights of 70 to 89 kg, and 140 mg for weights of 90 to 99 kg</li></ul><p>Placebo</p><ul><li><i>Number of randomised participants</i>: 58</li><li><i>Time from traumatic event to first intervention administration</i>: within 6 hours from the traumatic event</li><li><i>Intervention regimen</i>: equivalent placebo scheme</li></ul>",<p>PTSD severity</p><ul><li><b>Outcome type: </b>continuous outcome</li><li><b>Reporting:</b> fully reported</li><li><b>Scale: </b>CAPS</li><li><b>Time points:</b> 3 and 13 months post-traumatic event</li></ul><p>Dropout due to adverse events</p><ul><li><b>Outcome type</b>: dichotomous outcome</li><li><b>Reporting</b>: fully reported</li><li><b>Time points</b>: 3 months from the traumatic event</li></ul><p>PTSD rate</p><ul><li><b>Outcome type: </b>dichotomous outcome</li><li><b>Reporting:</b> fully reported</li><li><b>Scale: </b>CAPS (over 49 points)</li><li><b>Time points:</b> 3 and 13 months post-traumatic event</li></ul><p>Depression severity</p><ul><li><b>Outcome type: </b>continuous outcome</li><li><b>Reporting: </b>fully reported</li><li><b>Scale: </b>VAS-D (3 months) and MADRS (13 months)</li><li><b>Time points: </b>3 and 13 months post-traumatic event</li></ul><p>Anxiety severity</p><ul><li><b>Outcome type: </b>continuous outcome</li><li><b>Reporting: </b>fully reported</li><li><b>Scale: </b>VAS-A</li><li><b>Time points:</b> 3 and 13 months post-traumatic event</li></ul><p>Dropout for any reason</p><ul><li><b>Outcome type: </b>dichotomous outcome</li><li><b>Reporting: </b>fully reported</li><li><b>Time points: </b>3 and 13 months post-traumatic event</li></ul>,"<p><b>Sponsorship source: </b>the National Institutes of Health (NIH; Grant No. RO1 NCT00855270)</p><p><b>Country: </b>Israel</p><p><b>Author's name: </b>Joseph Zohar</p><p><b>Institution: </b>Post Trauma Center, Chaim Sheba Medical Center, Ramat Gan, Israel</p><p><b>Email: </b>Joseph.Zohar@sheba.health.gov.il</p><p><b>Address: </b>Anxiety and Stress Research Unit, Ministry of Health, Mental Health Center, Faculty of Health Sciences, Ben-Gurion University of the Negev, P.O. Box 4600, Beer Sheva 84170, Israel</p>",<p>Authors report no financial affiliation or other relationship relevant to the study</p>,<p>—</p>
Delahanty 2013,2013,PUB,23524748,,"<p><b>Study design: </b>RCT, parallel groups, double-blind, placebo-controlled</p><p><b>Number of centres: </b>1</p><p><b>Location: </b>""Midwestern Level-1 Trauma Unit""&nbsp;</p><p><b>Number of arms:</b> 2 (hydrocortisone versus placebo)</p><p><b>Follow-up time points:</b> 1 and 3 months after the traumatic event</p><p><b>Imputation strategy:</b> none</p><p><b>Original study outcomes (name, measure, time points): </b>PTSD rate and PTSD symptoms severity (Clinician-Administered PTSD Scale (CAPS)), Depressive symptoms (Center for Epidemiological Studies-Depression Scale (CES-D, self-reported)) and quality of life (SF-36, self-reported), all at 1 and 3 months post-injury</p>","<p><b>Sample size: </b>64</p><p><b>Baseline characteristics</b></p><p>Hydrocortisone</p><ul><li><i>Participants with a history of previous trauma</i>: not reported; 17 participants sought mental health treatment previously for the traumatic event</li><li><i>Type of traumatic event</i>: motor vehicle accident: 20, fall: 5, assault: 4, other: 2</li><li><i>Sex (F/M) and mean age (SD)</i>: 10/21, 27.2 (8.0)</li><li><i>Baseline acute traumatic stress symptoms (assessed within 12 hours from the traumatic event):</i> Peritraumatic Distress Inventory (PDI) mean score (SD): 2.3 (0.88); Peritraumatic Dissociative Experiences Questionnaire Self-Report Version (PDEQ) mean score (SD): 36.5 (5.6)</li></ul><p>Placebo</p><ul><li><i>Participants with a history of previous trauma</i>: not reported; 12 sought mental health treatment previously for the traumatic event</li><li><i>Type of traumatic event</i>: motor vehicle accident: 17, fall: 7, assault: 7, other: 2</li><li><i>Sex (F/M) and mean age (SD)</i>: 12/21 33.8 (12.0)</li><li><i>Baseline acute traumatic stress symptoms (assessed within 12 hours from the traumatic event): </i>Peritraumatic Distress Inventory (PDI) mean score (SD): 2.3 (0.97); Peritraumatic Dissociative Experiences Questionnaire Self-Report Version (PDEQ) mean score (SD): 34.5 (5.2)</li></ul><p><b>Baseline group differences: </b>placebo receivers were on average younger (33.8 ± 12.0 versus 27.2 ± 8.0); more hydrocortisone receivers had sought prior mental health treatment (Chi<sup>2</sup> = 3.61, P = 0.06) compared to placebo receivers</p><p><b>Inclusion criteria: </b>injury victims admitted as inpatients to trauma unit</p><p><b>Acute traumatic stress symptoms criterion:</b> score of at least 27 (mean score of 2.7 per item) on the 10-item Peritraumatic Dissociative Experiences Questionnaire Self-Report Version (PDEQ)</p><p><b>Exclusion criteria: </b>Glasgow Coma Scale (GCS) score of less than 14; exposure to a traumatic event that occurred more than 12 hours before initial medication dose could be given or inability to initiate first medication dose within 12 hours of event; allergy to cortisol or medical/medicinal contraindications to cortisol administration; pregnant or breastfeeding; exposure to a trauma of a potentially ongoing nature (e.g. domestic violence); presence of injuries requiring delayed operative procedures; patient-reported corticosteroid use in the previous 6 months; and/or patient had injuries that required treatment with steroids</p>","<p><b>Setting: </b>level 1 trauma unit</p><p><b>Intervention characteristics</b></p><p>Hydrocortisone</p><ul><li><i>Number of randomised participants</i>: 31</li><li><i>Time from traumatic event to first intervention administration</i>: within 12 hours</li><li><i>Intervention regimen</i>: 20 mg every 12 hours (twice a day) for 10 days, followed by a 6-day taper period (dose halved every 2 days)</li></ul><p>Placebo</p><ul><li><i>Number of randomised participants</i>: 33</li><li><i>Time from traumatic event to first intervention administration</i>: within 12 hours</li><li><i>Intervention regimen</i>: placebo tablets</li></ul>",<p>PTSD severity</p><ul><li><b>Outcome type</b>: continuous outcome</li><li><b>Reporting</b>: fully reported</li><li><b>Scale</b>: CAPS</li><li><b>Time points</b>: 3 months from the traumatic event</li></ul><p>Dropout due to adverse events</p><ul><li><b>Outcome type</b>: dichotomous outcome</li><li><b>Reporting</b>: fully reported</li><li><b>Time points</b>: 3 months from the traumatic event</li></ul><p>PTSD rate</p><ul><li><b>Outcome type</b>: dichotomous outcome</li><li><b>Reporting</b>: fully reported</li><li><b>Scale</b>: CAPS</li><li><b>Time points</b>: 3 months from the traumatic event</li></ul><p>Depression severity</p><ul><li><b>Outcome type</b>: continuous outcome</li><li><b>Reporting</b>: fully reported</li><li><b>Scale</b>: CES-D</li><li><b>Time points</b>: 3 months from the traumatic event</li></ul><p>Quality of life</p><ul><li><b>Outcome type</b>: continuous outcome</li><li><b>Reporting</b>: fully reported</li><li><b>Scale</b>: SF-36 (general health)</li><li><b>Time points</b>: 3 months from the traumatic event</li></ul><p>Dropout for any reason</p><ul><li><b>Outcome type</b>: dichotomous outcome</li><li><b>Reporting</b>: fully reported</li><li><b>Time points</b>: 3 months from the traumatic event</li></ul>,"<p><b>Sponsorship source:</b> study founded by the National Institute of Mental Health (R34 MH73014) and the Ohio Board of Regents</p><p><b>Country:</b> USA</p><p><b>Author's name:</b> Douglas L. Delahanty</p><p><b>Institution:</b> Kent State University, Department of Psychology, Kent, Ohio, USA and Department of Trauma Services, Akron, Ohio, USA</p><p><b>Email:</b> ddelahan@kent.edu</p><p><b>Address: </b>Douglas Delahanty, Department of Psychology, 144 Kent Hall, Kent, OH 44242, USA</p>","<p>One of the authors discloses speaker's honoraria (John Bon: The Medicine Company, speaker’s bureau, honoraria; Merck &amp; Co., speaker’s bureau, honoraria); all the remaining authors, including the leading researcher, report none.</p>",<p>—</p>
Mellman 2002,2002,PUB,23524751,,"<p><b>Study design: </b>RCT, parallel groups, double-blind, placebo-controlled</p><p><b>Number of centres: </b>1</p><p><b>Location:</b> USA</p><p><b>Number of arms:</b> 2 (temazepam versus placebo)</p><p><b>Follow-up time points: </b>1 day post intervention start, 1 week post-treatment, 6 weeks after initial assessment</p><p><b>Imputation strategy: </b>none</p><p><b>Original study outcomes (name, measure, time points): </b>total sleep hours and number of awakenings after first night of intervention and 1 week post-treatment; PTSD rate and symptoms severity (CAPS) at 1 week post-treatment and 6 weeks after initial assessment or just prior to initiating a non-study medication</p>","<p><b>Sample size:</b> 22</p><p><b>Baseline characteristics</b></p><p>Overall</p><ul><li><i>Participants with a history of previous trauma</i>: not reported</li><li><i>Type of traumatic event</i>: motor vehicle accidents: 15, industrial accidents: 2, interpersonal assault: 5</li><li><i>Sex (F/M) and mean age (SD)</i>: 8/14, 36.1 (11.4)</li><li><i>Baseline acute traumatic stress symptoms (exact assessment timing not specified): </i>full criteria for at least 2 DSM-IV PTSD symptom clusters (7 participants met full ASD criteria)</li></ul><p><b>Baseline group differences: </b>not reported</p><p><b>Inclusion criteria: </b>admission to a level 1 trauma centre following life-threatening incidents; having recall of the incident and endorsing at least moderate impairment of sleep initiation or maintenance</p><p><b>Acute traumatic stress symptoms criterion: </b>meeting full criteria for at least 2 PTSD symptom clusters (DSM-IV criteria)</p><p><b>Exclusion criteria: </b>being intoxicated at the time of the incident; brain injury and pre-existing active psychiatric disorders; inability or unwillingness to provide informed consent</p>","<p><b>Setting: </b>level 1 trauma centre</p><p><b>Intervention characteristics</b></p><p>Temazepam</p><ul><li><i>Number of randomised participants</i>: 11</li><li><i>Time from traumatic event to first intervention administration</i>: study medication initiated when medical/surgical stabilisation was achieved, a mean of 14.3 ± 10.0 days after the traumatic incident</li><li><i>Intervention regimen</i>: 30 mg at bedtime for 5 nights followed by 15 mg for 2 nights</li></ul><p>Placebo</p><ul><li><i>Number of randomised participants</i>: 11</li><li><i>Time from traumatic event to first intervention administration</i>: study medication initiated when medical/surgical stabilisation was achieved, a mean of 14.3 ± 10.0 days after the traumatic incident</li><li><i>Intervention regimen</i>: equivalent placebo scheme</li></ul>",<p>PTSD severity</p><ul><li><b>Outcome type</b>: continuous outcome</li><li><b>Reporting</b>: fully reported</li><li><b>Scale</b>: CAPS</li><li><b>Time points</b>: 6 weeks after initial assessment or just prior to initiating a non-study medication</li></ul><p>Dropout due to adverse events</p><ul><li><b>Outcome type</b>: dichotomous outcome</li><li><b>Reporting</b>: fully reported</li><li><b>Time points</b>: 6 weeks after initial assessment or just prior to initiating a non-study medication</li></ul><p>PTSD rate</p><ul><li><b>Outcome type</b>: dichotomous outcome</li><li><b>Reporting</b>: fully reported</li><li><b>Scale</b>: CAPS</li><li><b>Time points</b>: 6 weeks after initial assessment or just prior to initiating a non-study medication</li></ul><p>Dropout for any reason</p><ul><li><b>Outcome type</b>: dichotomous outcome</li><li><b>Reporting</b>: fully reported</li><li><b>Time points</b>: 6 weeks after initial assessment or just prior to initiating a non-study medication</li></ul>,"<p><b>Sponsorship source: </b>Grant MH54006 from the National Institute of Mental Health to Dr. Mellman</p><p><b>Country: </b>USA</p><p><b>Author's name: </b>Thomas A. Mellman</p><p><b>Institution: </b>Dartmouth Medical School Hanover, New Hampshire</p>",<p>Authors report no financial affiliation or other relationship relevant to the study</p>,<p>—</p>
Shalev 2012,2012,PUB,23524753,NCT00146900,"<p><b>Study design: </b>RCT, parallel groups. This study had 5 arms, of which only the SSRI and placebo ones are of interest for this review. For these 2 arms, the design was 'triple-blind' (participant, carer, assessor).</p><p><b>Number of centres: </b>1</p><p><b>Location: </b>Jerusalem, Israel</p><p><b>Number of arms:</b> 5: escitalopram versus placebo, plus 3 non-pharmacological arms (prolonged exposure (PE), cognitive therapy (CT), waiting list (WL))</p><p><b>Follow-up time points: </b>5 months, 9 months, 3 years after the traumatic event</p><p><b>Imputation strategy: </b>none for the outcomes of interest</p><p><b>Original study outcomes (name, measure, time points): </b>PTSD symptoms and PTSD prevalence assessed by CAPS, depression severity (Beck Depression Inventory (BDI)), DSM-IV axis I disorder other than PTSD (The Structured Clinical Interview for DSM-IV (SCID-IV)) and functional disability (Global Assessment of Functioning (GAF)); all of them at 5, 9 months and 3 years post-trauma</p>","<p><b>Sample size: </b>sample size of escitalopram/placebo arms: 46 (sample size including non-pharmacological arms: 242)</p><p><b>Baseline characteristics</b></p><p>Escitalopram</p><ul><li><i>Participants with a history of previous trauma</i>: not reported</li><li><i>Type of traumatic event</i>: motor vehicle accident: 21, terrorist attack: 0; other: 2</li><li><i>Sex (F/M) and mean age (SD)</i>: 13/10, 39.83 (11.74)</li><li><i>Baseline acute traumatic stress symptoms (assessment took place at mean 19.8 days (SD 5.2) after the traumatic event): </i>CAPS score at baseline (SD) 79.83 (15.60)</li></ul><p>Placebo</p><ul><li><i>Participants with a history of previous trauma</i>: not reported</li><li><i>Type of traumatic event</i>: motor vehicle accident: 20, terrorist attack: 2; other: 1</li><li><i>Sex (F/M) and mean age (SD)</i>: 10/13, 36.26 (12.39)</li><li><i>Baseline acute traumatic stress symptoms (assessment took place at mean 19.8 days (SD 5.2) after the traumatic event): </i>CAPS score at baseline (SD) 74.91 (14.69)</li></ul><p><b>Baseline group differences: </b>none reported</p><p><b>Inclusion criteria: </b>adult traumatic event (DSM-IV PTSD criterion A) survivors admitted to Hadassah University Hospital's emergency services; resided within a 1-hour drive from Jerusalem (could attend treatment)</p><p><b>Acute traumatic stress symptoms criterion: </b>meeting DSM-IV PTSD (save the 1-month duration) criteria either fully or partially (2 out of 3 PTSD symptom criteria (B, C, and D))</p><p><b>Exclusion criteria: </b>injury requiring more than 7 days of hospital stay, unconscious on admission to emergency services, medical or surgical conditions that interfered with their ability to participate or provide informed consent, not fluent enough in Hebrew, Arabic or English; current or past psychosis or bipolar disorder, current substance abuse problem, other conditions requiring urgent attention (e.g. suicidal ideations or acute grief) or chronic PTSD; started treatment elsewhere</p>","<p><b>Setting: </b>post hospital emergency department admission</p><p><b>Intervention characteristics</b></p><p>Escitalopram</p><ul><li><i>Number of randomised participants</i>: 23</li><li><i>Time from traumatic event to first intervention administration (SD)</i>: 29.35 (4.91) days</li><li><i>Intervention regimen</i>: 10 mg tablets: 1 tablet daily for 2 weeks, then 2 tablets daily for 10 weeks</li></ul><p>Placebo</p><ul><li><i>Number of randomised participants</i>: 23</li><li><i>Time from traumatic event to first intervention administration (SD)</i>: 28.91 (5.71) days</li><li><i>Intervention regimen</i>: equivalent placebo scheme</li></ul>",<p>PTSD severity</p><ul><li><b>Outcome type</b>: continuous outcome</li><li><b>Reporting</b>: fully reported</li><li><b>Scale</b>: CAPS</li><li><b>Time points</b>: 3 years after the traumatic event</li></ul><p>PTSD rate</p><ul><li><b>Outcome type</b>: dichotomous outcome</li><li><b>Reporting</b>: fully reported</li><li><b>Scale</b>: CAPS</li><li><b>Time points</b>: 3 years after the traumatic event</li></ul><p>Depression severity</p><ul><li><b>Outcome type</b>: continuous outcome</li><li><b>Reporting</b>: fully reported</li><li><b>Scale</b>: BDI</li><li><b>Time points</b>: 3 years after the traumatic event</li></ul><p>Functional disability</p><ul><li><b>Outcome type</b>: continuous outcome</li><li><b>Reporting</b>: fully reported</li><li><b>Scale</b>: SCID IV GAF (higher is better)</li><li><b>Time points</b>: 3 years after the traumatic event</li></ul><p>Dropout for any reason</p><ul><li><b>Outcome type</b>: dichotomous outcome</li><li><b>Reporting</b>: fully reported</li><li><b>Time points: </b>3 years after the traumatic event</li></ul>,"<p><b>Sponsorship source: </b>The study was sponsored by the Jerry Lee Foundation in Philadelphia, Pennsylvania, USA, Jewish Federation of New York, research grant MH071651 from the National Institute of Mental Health, and an investigator-initiated research grant from Lundbeck Pharmaceuticals Ltd (Denmark).</p><p><b>Author's name: </b>Arieh Y. Shalev</p><p><b>Institution: </b>Center for Traumatic Stress Studies, Department of Psychiatry, Hadassah University Hospital, Jerusalem, Israel</p><p><b>Email: </b>arieh.shalev@nyumc.org</p><p><b>Address: </b>Arieh Y. Shalev, MD, Department of Psychiatry, Hadassah University Hospital, PO Box 12000, Kiriat Hadassah–Ein Kerem, Jerusalem 91120, Israel</p>","<p>Dr Shalev received an investigator-initiated grant from Lundbeck Pharmaceuticals Ltd for this study and for an ongoing collaborative study (Joseph Zohar, MD, principal investigator) entitled “Prevention of PTSD by Escitalopram.” No conflicts of interest to declare from the other co-authors.</p>",<p>This trial has 5 arms; only the escitalopram/placebo arms have been considered in this review.</p>
Suliman 2015,2015,PUB,23524759,NCT00300313,"<p><b>Study design:</b> RCT, double-blind, parallel groups, placebo-controlled pilot study</p><p><b>Number of centres: </b>1 (University of Cape Town affiliated hospitals)</p><p><b>Primary location: </b>Cape Town, South Africa</p><p><b>Number of arms:</b> 2 (escitalopram versus placebo)</p><p><b>Follow-up time points: </b>every 2 weeks until visit 8 and thereafter every 4 weeks</p><p><b>Imputation strategy: </b>none</p><p><b>Original study outcomes (name, measure, time points): </b>Primary: CAPS score and CAPS determined PTSD rate. Secondary: Clinical Global Impression - Severity and Improvement scales (CGI), Mini International Neuropsychiatric Interview (MINI 5.0.0), Montgomery-Asberg Depression Rating Scale (MADRS), Visual Analogue Scale for Depression (VAS-D), Visual Analogue Scale for Anxiety (VAS-A), Sheehan Disability Scale (SDS). All of them at weeks 0, 4, 12, 24, 32, 40, 48 and 56 (visits 2, 4, 8, 11, 13, 15, 17, 19)</p>","<p><b>Sample size: </b>31</p><p><b>Baseline characteristics</b></p><p>(Baseline characteristics were provided only for the 29 participants that completed the trial)</p><p>Escitalopram</p><ul><li><i>Participants with a history of previous trauma</i>: not reported</li><li><i>Type of traumatic event</i>: assault (physical/sexual): 10, other (MVA/witnessing event): 2</li><li><i>Sex (F/M) and mean age (SD)</i>: 5/7, 31.33 (7.85)</li><li><i>Baseline acute traumatic stress symptoms (exact timing of assessment not reported): </i>baseline CAPS score (SD): 45.33 (21.43), all 12 meeting full ASD criteria</li></ul><p>Placebo</p><ul><li><i>Participants with a history of previous trauma</i>: not reported</li><li><i>Type of traumatic event</i>: assault (physical/sexual): 10, other (MVA/witnessing event): 7</li><li><i>Sex (F/M) and mean age (SD)</i>: 5/12, 28.24 (8.38)</li><li><i>Baseline acute traumatic stress symptoms (exact timing of assessment not reported): </i>baseline CAPS score (SD): 62.00 (22.98); 15 meeting full ASD criteria, 2 meeting partial ASD criteria</li></ul><p><b>Baseline group differences: </b>ethnicity: no coloured/mixed race participants in escitalopram group</p><p><b>Inclusion criteria: </b>experience of a traumatic event, such as a vehicle collision or other accident, physical or sexual assault within the previous 4 weeks; between 18 and 65 years of age; sufficient knowledge of English in order to read, understand and sign the Informed Consent form as well as study procedures and assessment instruments</p><p><b>Acute traumatic stress symptoms criterion: </b>presence of either full DSM-IV criteria or intrusion and hyper-arousal criteria for ASD</p><p><b>Exclusion criteria: </b>refusal of any medication therapy; serious physical injury (Abbreviated Injury Scale (AIS) score of 3 or more); concomitant medications not allowed in the study (monoamine oxidase inhibitors (MAOIs), reversible inhibitors of monoamine oxidase A (RIMAs), mood stabilisers, antipsychotics or psychoactive herbal remedies within the 3 weeks prior to screening, anxiolytics or serotonergic agonists within the 2 weeks prior to screening, treatment with any anticonvulsant drug); lifetime DSM-IV-TR criteria for mania or bipolar disorder, schizophrenia, any personality disorder, mental retardation or pervasive developmental disorder, or cognitive disorder; significant suicide risk and/or a score of = 5 on item 10 of the Montgomery Asberg Depression Rating Scale (MADRS) scale; history of severe suicide attempt; electroconvulsive therapy within the last year; currently serving in the South African security forces.; history of drug allergy or hypersensitivity to escitalopram or citalopram; illness severe enough to prevent participation in the study (including liver or renal insufficiency; cardiovascular, pulmonary, gastrointestinal, endocrine (including uncontrolled thyroid), neurological (including epilepsy), infectious, neoplastic or metabolic disturbances; pregnant or breastfeeding; refusal of adequate contraceptive use (if female)</p>","<p><b>Setting: </b>emergency department</p><p><b>Intervention characteristics</b></p><p>Escitalopram</p><ul><li><i>Number of randomised participants</i>: 13</li><li><i>Time from traumatic event to first intervention administration</i>: not reported</li><li><i>Intervention regimen</i>: 10 mg daily for 4 weeks, then 20 mg daily for 20 weeks. Down-titration for intolerable side effects allowed.</li></ul><p>Placebo</p><ul><li><i>Number of randomised participants</i>: 18</li><li><i>Time from traumatic event to first intervention administration</i>: not reported</li><li><i>Intervention regimen</i>: equivalent placebo scheme</li></ul>",<p>PTSD severity</p><ul><li><b>Outcome type</b>: continuous outcome</li><li><b>Reporting</b>: personal communication and paper reported data</li><li><b>Scale</b>: CAPS</li><li><b>Time points</b>: 12 and 24 weeks</li></ul><p>Dropout due to adverse events</p><ul><li><b>Outcome type</b>: dichotomous outcome</li><li><b>Reporting</b>: personal communication</li><li><b>Time points</b>: 12 and 56 weeks</li></ul><p>PTSD rate</p><ul><li><b>Outcome type</b>: dichotomous outcome</li><li><b>Reporting</b>: personal communication and paper reported data</li><li><b>Scale</b>: CAPS</li><li><b>Time points</b>: 12 and 56 weeks</li></ul><p>Depression severity</p><ul><li><b>Outcome type</b>: continuous outcome</li><li><b>Reporting</b>: personal communication</li><li><b>Scale</b>: MADRS</li><li><b>Time points</b>: 12 and 56 weeks</li></ul><p>Anxiety severity</p><ul><li><b>Outcome type</b>: continuous outcome</li><li><b>Reporting</b>: personal communication</li><li><b>Scale</b>: VAS-A</li><li><b>Time points</b>: 12 and 56 weeks</li></ul><p>Dropout for any reason</p><ul><li><b>Outcome type</b>: dichotomous outcome</li><li><b>Reporting</b>: personal communication</li><li><b>Time points</b>: 12 and 56 weeks</li></ul>,"<p><b>Sponsorship source: </b>Lundbeck A/S</p><p><b>Country: </b>South Africa</p><p><b>Author's name: </b>Sharain Suliman</p><p><b>Institution: </b>MRC Anxiety Disorders Unit, Department of Psychiatry, Stellenbosch University, Cape Town, South Africa</p><p><b>Email: </b>sharain@sun.ac.za</p>","<p>S Suliman has received research grants from the Stellenbosch University Faculty of Health Sciences, Hendrik Vrouwes Research Scholarship, and South African National Research Foundation (Thuthuka). DJ Stein has received research grants and/or consultancy honoraria from Abbott, Astrazeneca, Eli-Lilly, GlaxoSmithKline, Jazz Pharmaceuticals, Johnson &amp; Johnson, Lundbeck, Orion, Pfizer, Pharmacia, Roche, Servier, Solvay, Sumitomo, Takeda, Tikvah, and Wyeth. S Seedat is supported by South African Research Chairs Initiative (SARChI) hosted by the Department of Science and Technology and the National Research Foundation, South Africa.</p>",<p>—</p>
Van Zuiden 2017,2017,PUB,23524761,,"<p><b>Study design: </b>RCT, double-blind, parallel groups, placebo-controlled</p><p><b>Number of centres: </b>3 emergency departments in Amsterdam, the Netherlands (academic level 1 trauma centres: Academic Medical Center, VU University Medical Center; level 2 trauma centre: Onze Lieve Vrouwe Gasthuis Hospital West)</p><p><b>Number of arms:</b> 2 (oxytocin and placebo)</p><p><b>Follow-up time points: </b>1.5, 3 and 6 months post-trauma</p><p><b>Imputation strategy: </b>pooled results of 40 generated datasets using multiple imputation for missing outcome data for the CAPS and HADS scores using as auxiliary variables the intervention, demographic, trauma and baseline clinical characteristics</p><p><b>Original study outcomes (name, measure, time points): </b>Primary: PTSD symptoms severity (CAPS) at 1.5 months post-trauma. Secondary: PTSD symptoms severity (CAPS) at 3 and 6 months post-trauma; self-reported PTSD symptoms severity (IES-R), depression and anxiety (Hospital Anxiety and Depression Scale (HADS)) at 1.5, 3 and 6 months post-trauma</p>","<p><b>Sample size: </b>120</p><p><b>Baseline characteristics</b></p><p>(Baseline characteristics were provided for the 107 participants who started the assigned intervention; 2 of the non-starters had exclusion criteria that emerged after the randomisation).</p><p>Oxytocin</p><ul><li><i>Participants with a history of previous trauma</i>: not reported</li><li><i>Type of traumatic event</i>: accidental: 43, assault: 10</li><li><i>Sex (F/M) and mean age (SD)</i>: 27/26, 35.00 (13.13)</li><li><i>Baseline acute traumatic stress symptoms (assessed within 10 days from the traumatic event): </i>CAPS (SD): 42.83 (16.93)</li></ul><p>Placebo</p><ul><li><i>Participants with a history of previous trauma</i>: not reported</li><li><i>Type of traumatic event</i>: accidental: 48, assault: 6</li><li><i>Sex (F/M) and mean age (SD)</i>: 26/28, 35.91 (13.30)</li><li><i>Baseline acute traumatic stress symptoms (assessed within 10 days from the traumatic event):</i> CAPS (SD): 41.28 (20.96)</li></ul><p><b>Baseline group differences: </b>no baseline imbalances</p><p><b>Inclusion criteria: </b>admission to emergency department after experiencing a traumatic event, 18 to 65 years of age</p><p><b>Acute traumatic stress symptoms criterion: </b>scoring ≥ 5 on the Trauma Screening Questionnaire (TSQ) and ≥ 17 on the Peritraumatic Distress Inventory (PDI) screening questionnaire</p><p><b>Exclusion criteria: </b>current PTSD or depression; psychotic, bipolar, substance-related and personality disorder; severe/chronic systemic disease; mental retardation; neurological/endocrine disorder; ongoing traumatisation; medications potentially interfering with oxytocin administration (e.g. systemic glucocorticoids or psychotropic medications); oxytocin allergy; persistent impaired consciousness or amnesia; pregnancy; and breastfeeding</p>","<p><b>Setting: </b>emergency department</p><p><b>Intervention characteristics</b></p><p>Oxytocin</p><ul><li><i>Number of randomised participants</i>: 58</li><li><i>Time from traumatic event to first intervention administration</i>: overall for both interventions, mean of 8.94 (1.80) days, within 12 days from trauma</li><li><i>Intervention regimen</i>: intranasal administration: 5 puffs of 4 IU per nostril twice a day, for 8 days</li></ul><p>Placebo</p><ul><li><i>Number of randomised participants</i>: 62</li><li><i>Time from traumatic event to first intervention administration</i>: overall for both interventions, mean of 8.94 (1.80) days, within 12 days from trauma</li><li><i>Intervention regimen</i>: equivalent scheme with 0.9% NaCl solution</li></ul>",<p>PTSD severity</p><ul><li><b>Outcome type</b>: continuous outcome</li><li><b>Reporting</b>: fully reported</li><li><b>Scale</b>: CAPS</li><li><b>Time points</b>: 3 and 6 months post-traumatic event</li></ul><p>Depression severity</p><ul><li><b>Outcome type</b>: continuous outcome</li><li><b>Reporting</b>: fully reported</li><li><b>Scale</b>: Hospital Anxiety and Depression Scale (HADS)</li><li><b>Time points</b>: 3 and 6 months post-traumatic event</li></ul><p>Anxiety severity</p><ul><li><b>Outcome type</b>: continuous outcome</li><li><b>Reporting</b>: fully reported</li><li><b>Scale</b>: Hospital Anxiety and Depression Scale (HADS)</li><li><b>Time points</b>: 3 and 6 months post-traumatic event</li></ul><p>Dropout for any reason</p><ul><li><b>Outcome type</b>: dichotomous outcome</li><li><b>Reporting</b>: fully reported</li><li><b>Time points</b>: 3 and 6 months post-traumatic event</li></ul>,"<p><b>Sponsorship source: </b>Supported by grants from the Netherlands Organisation for Health Research and Development (Grant No. 91210041) and from the Academic Medical Center Research Council (Grant No. 110614).</p><p><b>Country: </b>the Netherlands</p><p><b>Author's name: </b>Mirjam van Zuiden</p><p><b>Institution: </b>Department of Psychiatry, Academic Medical Center, University of Amsterdam, VU University Medical Center, Amsterdam</p><p><b>Email: </b>m.vanzuiden@amc.nl</p>",<p>Authors report no biomedical financial interests or potential conflicts of interest.</p>,<p>—</p>
Zohar 2011,2011,PUB,23524775,NCT00855270,"<p><b>Study design: </b>RCT, parallel groups, double-blind, placebo-controlled pilot study</p><p><b>Number of centres: </b>1</p><p><b>Location: </b>Israel</p><p><b>Number of arms:</b> 2 (hydrocortisone and placebo)</p><p><b>Follow-up time points: </b>2 weeks, 1 and 3 months post-trauma</p><p><b>Imputation strategy: </b>none</p><p><b>Original study outcomes (name, measure, time points): </b>PTSD rate and symptoms severity (CAPS), anxiety (Visual Analogue Scale for Anxiety (VAS-A)) and depression (Visual Analogue Scale for Depression (VAS-D)), at 2 weeks, 1 and 3 months post-trauma</p>","<p><b>Sample size: </b>25</p><p><b>Baseline characteristics</b></p><p>Hydrocortisone</p><ul><li><i>Participants with a history of previous trauma</i>: not reported</li><li><i>Type of traumatic event</i>: work accident: 1, motor vehicle accident: 7, snake bite: 1</li><li><i>Sex (F/M) and mean age (SD)</i>: 6/3, 36.1 (15.9)</li><li><i>Baseline acute traumatic stress symptoms (assessed before intervention administration): </i>VAS anxiety: 4.3 (3.2)</li></ul><p>Placebo</p><ul><li><i>Participants with a history of previous trauma</i>: not reported</li><li><i>Type of traumatic event</i>: work accident: 3, motor vehicle accident: 5, snake bite: 0</li><li><i>Sex (F/M) and mean age (SD)</i>: 2/6, 34.4 (12.1)</li><li><i>Baseline acute traumatic stress symptoms (assessed before intervention administration): </i>VAS anxiety: 5.1 (4.6)</li></ul><p><b>Baseline group differences: </b>no baseline group imbalances</p><p><b>Inclusion criteria: </b>admission to the emergency department of Chaim Sheba Medical Center, exposure to a traumatic event</p><p><b>Acute traumatic stress symptoms criteria: </b>experience of either acute stress reaction or sub-threshold acute stress reaction, meeting the DSM-IV PTSD A.1 (stressor) and A.2 (response) criteria (fulfilling criteria A, 2 of the symptoms in criteria B, 3 out of 4 of criteria C, D, E and F, and meeting criterion H of the ASD criteria set out in DSM-IV)</p><p><b>Exclusion criteria: </b>serious physical injury (a score of 3 or above on the Abbreviated Injury Scale), brain trauma, substance abuse disorders, cardiac pacemaker implant, a history of epilepsy, neurosurgery, chronic medical conditions of any sort. Hypersensitivity to hydrocortisone, pregnancy, or treatment for asthma.</p>","<p><b>Setting: </b>emergency department</p><p><b>Intervention characteristics</b></p><p>Hydrocortisone</p><ul><li><i>Number of randomised participants</i>: 15</li><li><i>Time from traumatic event to first intervention administration</i>: between 1.5 and 5.5 hours from the traumatic event</li><li><i>Intervention regimen</i>: single intravenous bolus at a dose based on body weight: 100 mg for weights of 60 to 69 kg, 120 mg for weights of 70 to 89 kg and 140 mg for weights of 90 to 99 kg</li></ul><p>Placebo</p><ul><li><i>Number of randomised participants</i>: 10</li><li><i>Time from traumatic event to first intervention administration</i>: between 1.5 and 5.5 hours from the traumatic event</li><li><i>Intervention regimen</i>: equivalent placebo scheme</li></ul>","<p>PTSD severity</p><ul><li><b>Outcome type</b>: continuous outcome</li><li><b>Reporting</b>: data reported in figure, extracted by plot digitiser</li><li><b>Scale</b>: CAPS</li><li><b>Time points</b>: 3 months post-traumatic event</li></ul><p>PTSD rate</p><ul><li><b>Outcome type</b>: dichotomous outcome</li><li><b>Reporting</b>: fully reported</li><li><b>Scale</b>: CAPS</li><li><b>Time points</b>: 3 months post-traumatic event</li></ul><p>Depression severity</p><ul><li><b>Outcome type</b>: continuous outcome</li><li><b>Reporting</b>: data reported in figure, extracted by plot digitiser</li><li><b>Scale</b>: VAS-D</li><li><b>Time points</b>: 3 months post-traumatic event</li></ul><p>Anxiety severity</p><ul><li><b>Outcome type</b>: continuous outcome</li><li><b>Reporting</b>: data reported in figure, extracted by plot digitiser</li><li><b>Scale</b>: VAS-A</li><li><b>Time points</b>: 3 months post-traumatic event</li></ul><p>Dropout for any reason</p><ul><li><b>Outcome type</b>: dichotomous outcome</li><li><b>Reporting</b>: fully reported</li><li><b>Time points</b>: 3 months post-traumatic event</li></ul>","<p><b>Sponsorship source: </b>The National Institute for Psychobiology in Israel, funded by Charles E. Smith Family, The Israel Academy of Science and Humanities (grant #416/09) and the Ministry of Health (grant #3-0000-6086)</p><p><b>Country: </b>Israel</p><p><b>Author's name: </b>Joseph Zohar</p><p><b>Institution: </b>Division of Psychiatry, The State of Israel Ministry of Health, The Chaim Sheba Medical Center, Sackler Medical School, Tel-Aviv University, Tel Hashomer</p><p><b>Email: </b>hagitc@bgu.ac.il</p><p><b>Address: </b>Anxiety and Stress Research Unit, Ministry of Health, Mental Health Center, Faculty of Health Sciences, Ben-Gurion University of the Negev, P.O. Box 4600, Beer Sheva 84170, Israel</p>",<p>Authors report no financial affiliation or other relationship relevant to the study.</p>,"<p>This is a pilot trial for&nbsp;<a type=""STUDY"" href=""439933378453659309"">Carmi 2022</a>.</p>"
Zohar 2018,2018,PUB,23524781,NCT00300313,"<p><b>Study design: </b>RCT, parallel groups, double-blind, placebo-controlled</p><p><b>Number of centres:</b> 5</p><p><b>Locations: </b>5 medical centres in Israel and 1 medical centre in South Africa</p><p><b>Number of arms:</b> 2 (escitalopram versus placebo)</p><p><b>Follow-up time points: </b>at end of treatment phase (12 to 24 weeks - most of the sample (91%) concluded 24 weeks of treatment) and after 56 weeks</p><p><b>Imputation strategy: </b>none</p><p><b>Original study outcomes (name, measure, time points): </b>Primary outcome: CAPS score difference from baseline to follow-up; secondary outcomes: PTSD symptoms scale self-rated (PSS-SR), Pittsburgh Sleep Quality Index (PSQI), Montgomery-Asberg Depression Rating Scale (MADRS), Clinical Global Impressions Severity of Illness scale (CGI-S) and Improvement scale (CGI-I), self-report visual analogue scale (VAS) for depression and anxiety. Outcomes measured at end of treatment (12 to 24 weeks - most of the sample (91%) concluded 24 weeks of treatment) and at 56 weeks.</p>","<p><b>Sample size: </b>353</p><p><b>Baseline characteristics</b></p><p>(Baseline characteristics were provided for completers only).</p><p>Escitalopram (102)</p><ul><li><i>Participants with a history of previous trauma</i>: not reported</li><li><i>Type of traumatic event</i>: intentional: 78, unintentional: 24</li><li><i>Sex (F/M) and mean age (SD)</i>: 42/60, 39.6 (13.2)</li><li><i>Baseline acute traumatic stress symptoms (SD) (exact timing of assessment not reported): </i>CAPS: 71.9 (22.1)</li></ul><p>Placebo (96)</p><ul><li><i>Participants with a history of previous trauma</i>: not reported</li><li><i>Type of traumatic event</i>: intentional: 70, unintentional: 26</li><li><i>Sex (F/M) and mean age (SD)</i>: 55/41, 39.1 (12.2)</li><li><i>Baseline acute traumatic stress symptoms (SD) (exact timing of assessment not reported): </i>CAPS: 72.8 (21.8)</li></ul><p><b>Baseline group differences: </b>the escitalopram group had significantly more men than the placebo group</p><p><b>Inclusion criteria: </b>exposure to a traumatic event within the prior month; between the ages of 18 and 65 years</p><p><b>Acute traumatic stress symptoms criterion: </b>met at least 2 DSM-IV criteria for acute stress disorder (re-experiencing and hyperarousal)</p><p><b>Exclusion criteria: </b>serious injury (Abbreviated Injury Scale score ≥ 3); diagnosis (DSM-IV) of bipolar disorder, schizophrenia or personality disorder; a history of alcohol or drug abuse, mental retardation, or dementia; having significant suicide risk or a past serious suicide attempt, as evaluated by the Mini-International Neuropsychiatric Interview (MINI); therapy with psychiatric medications, (medications for depression, psychosis, or relapse prevention (mood stabilisers)); participation in psychotherapy; electroconvulsive treatment within the previous year; sensitivity to citalopram or escitalopram; any major physical illness; being pregnant or lactating; and being of childbearing age and not using contraceptives</p>","<p><b>Setting: </b>emergency department</p><p><b>Intervention characteristics</b></p><p>Escitalopram</p><ul><li><i>Number of randomised participants</i>: 176</li><li><i>Time from traumatic event to first intervention administration</i>: within 1 month from the traumatic event</li><li><i>Intervention regimen</i>: flexible length: no less than 12 weeks, up to 24 weeks; starting dose of 10 mg/day and then gradual titration to 20 mg/day during the first 4 weeks</li></ul><p>Placebo</p><ul><li><i>Number of randomised participants</i>: 177</li><li><i>Time from traumatic event to first intervention administration</i>: within 1 month from the traumatic event</li><li><i>Intervention regimen</i>: equivalent placebo scheme</li></ul>","<p>PTSD severity</p><ul><li><b>Outcome type</b>: continuous outcome</li><li><b>Reporting</b>: data reported in figure, extracted by plot digitiser</li><li><b>Scale</b>: CAPS</li><li><b>Time points</b>: 56 weeks post-traumatic event</li></ul><p>Depression severity</p><ul><li><b>Outcome type</b>: continuous outcome</li><li><b>Reporting</b>: not reported in enough detail to meta-analyse</li><li><b>Scale</b>: MADRS</li></ul><p>Anxiety severity</p><ul><li><b>Outcome type</b>: continuous outcome</li><li><b>Reporting</b>: not reported in enough detail to meta-analyse</li><li><b>Scale</b>: VAS-A</li></ul><p>Dropout for any reason</p><ul><li><b>Outcome type</b>: dichotomous outcome</li><li><b>Reporting</b>: fully reported</li><li><b>Time points</b>: 56 weeks post-traumatic event</li></ul>","<p><b>Sponsorship source: </b>Lundbeck A/S</p><p><b>Country: </b>Israel, South Africa</p><p><b>Author's name: </b>Joseph Zohar</p><p><b>Institution: </b>Department of Psychiatry, Chaim Sheba Medical Center, Tel Hashomer, Israel</p><p><b>Email: </b>jzohar@post.tau.ac.il</p><p><b>Address: </b>Joseph Zohar, MD, Department of Psychiatry, Chaim Sheba Medical Center, Tel Hashomer, Israel 52621</p>","<p>Dr Zohar has received grant/research support from Lundbeck, Servier, and Pfizer; has served as a consultant or on advisory boards for Servier, Pfizer, Abbott, Lilly, Actelion, AstraZeneca, and Roche; and has served on speakers’ bureaus for Lundbeck, Roche, and Abbott. Dr Juven-Wetzler has served on speakers’ bureaus for Pfizer. Dr H. Shalev served on speakers’ bureaus for Eli Lilly and Unifarm between 2008 and 2011. In the past 3 years, Dr Stein has received research grants and/or consultancy honoraria from Biocodex, Lundbeck, Novartis, Servier, and Sun Lifetime; has received research grants and/or consultancy honoraria from Abbott, Astrazeneca, Biocodex, Eli Lilly, GlaxoSmithKline, Jazz, Johnson &amp; Johnson, Lundbeck, Novartis, Orion, Pfizer, Pharmacia, Roche, Servier, Solvay, Sumitomo, Sun, Takeda, Tikvah, and Wyeth. Dr Suliman has received research grants from the Stellenbosch University Faculty of Health Sciences, Hendrik Vrouwes Research Scholarship, and South African National Research Foundation (Thuthuka). Drs Fostick, Kaplan, Schreiber, Miroshnik, A. Y. Shalev, Seedat, and Klein have no financial interests or other conflicts to disclose.</p>",<p>—</p>
